JP2011505140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505140A5 JP2011505140A5 JP2010536117A JP2010536117A JP2011505140A5 JP 2011505140 A5 JP2011505140 A5 JP 2011505140A5 JP 2010536117 A JP2010536117 A JP 2010536117A JP 2010536117 A JP2010536117 A JP 2010536117A JP 2011505140 A5 JP2011505140 A5 JP 2011505140A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- polynucleotide
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 239000002157 polynucleotide Substances 0.000 claims 9
- 102000040430 polynucleotide Human genes 0.000 claims 9
- 108091033319 polynucleotide Proteins 0.000 claims 9
- 125000000539 amino acid group Chemical group 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000009123 Fibrin Human genes 0.000 claims 2
- 108010073385 Fibrin Proteins 0.000 claims 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 229950003499 fibrin Drugs 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 108010088842 Fibrinolysin Proteins 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 241001228709 Suruga Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010015052 miniplasmin Proteins 0.000 claims 1
- 229940012957 plasmin Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99114807P | 2007-11-29 | 2007-11-29 | |
| US60/991,148 | 2007-11-29 | ||
| PCT/US2008/084645 WO2009073471A1 (en) | 2007-11-29 | 2008-11-25 | Recombinantly modified plasmin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011505140A JP2011505140A (ja) | 2011-02-24 |
| JP2011505140A5 true JP2011505140A5 (https=) | 2012-01-19 |
| JP5539896B2 JP5539896B2 (ja) | 2014-07-02 |
Family
ID=40379999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010536117A Active JP5539896B2 (ja) | 2007-11-29 | 2008-11-25 | 組換え的に改変されたプラスミン |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8101394B2 (https=) |
| EP (1) | EP2220221B1 (https=) |
| JP (1) | JP5539896B2 (https=) |
| KR (1) | KR101529743B1 (https=) |
| CN (1) | CN101918548B (https=) |
| AU (1) | AU2008331545B2 (https=) |
| BR (1) | BRPI0819780B1 (https=) |
| CA (1) | CA2707266C (https=) |
| ES (1) | ES2534040T3 (https=) |
| HU (1) | HUE024916T2 (https=) |
| IL (1) | IL205936A (https=) |
| MX (1) | MX2010005947A (https=) |
| NZ (2) | NZ593837A (https=) |
| PL (1) | PL2220221T3 (https=) |
| PT (1) | PT2220221E (https=) |
| WO (1) | WO2009073471A1 (https=) |
| ZA (1) | ZA201003730B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102660564B (zh) | 2004-04-22 | 2013-05-08 | 泰勒克里斯生物治疗学公司 | 重组修饰的纤溶酶 |
| PL2220221T3 (pl) | 2007-11-29 | 2015-07-31 | Grifols Therapeutics Inc | Rekombinacyjnie zmodyfikowana plazmina |
| MX2010013282A (es) | 2008-06-04 | 2010-12-21 | Talecris Biotherapeutics Inc | Composicion, metodo y kit para la preparacion de plasmina. |
| HUE025670T2 (en) * | 2009-03-03 | 2016-04-28 | Grifols Therapeutics Inc | A method for producing plasminogen |
| WO2011004011A1 (en) | 2009-07-10 | 2011-01-13 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| ES2534911T3 (es) | 2009-08-28 | 2015-04-30 | Thrombogenics N.V. | Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía |
| CN102121023B (zh) * | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| JP6085568B2 (ja) | 2011-01-05 | 2017-02-22 | スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ | プラスミノーゲンおよびプラスミンの変異体 |
| US9644196B2 (en) | 2011-08-12 | 2017-05-09 | Thrombogenics Nv | Plasminogen and plasmin variants |
| CN103205410B (zh) * | 2012-01-13 | 2018-03-06 | 蔺莹莹 | 重组微纤维蛋白溶酶及其制备方法和应用 |
| SG11201506886TA (en) | 2013-03-14 | 2015-09-29 | Bayer Healthcare Llc | Monoclonal antibodies against antithrombin beta complexed with heparin |
| DE102014112212A1 (de) * | 2014-08-26 | 2016-03-03 | Akesion Gmbh | Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen |
| FR3035120B1 (fr) * | 2015-04-15 | 2020-02-07 | Arcadophta | Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition |
| WO2017101870A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗糖尿病性视网膜病变的方法 |
| TWI725092B (zh) | 2015-12-18 | 2021-04-21 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途 |
| TWI624268B (zh) | 2015-12-18 | 2018-05-21 | Talengen Institute Of Life Sciences Co Ltd | 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑 |
| WO2017101867A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 |
| CN108210897A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗肺纤维化的药物及其用途 |
| WO2018107707A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种改善心脏病变的方法 |
| JP7175270B2 (ja) * | 2016-12-15 | 2022-11-18 | タレンゲン インターナショナル リミテッド | グルカゴン、インスリンを正常なバランスに戻らせる方法 |
| US11207387B2 (en) | 2016-12-15 | 2021-12-28 | Talengen International Limited | Method and drug for preventing and treating obesity |
| WO2018107688A1 (zh) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗脂肪肝的方法 |
| US11154595B2 (en) | 2016-12-15 | 2021-10-26 | Talengen International Limited | Method for preventing and treating pulmonary fibrosis |
| CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| US11140020B1 (en) | 2018-03-01 | 2021-10-05 | Amazon Technologies, Inc. | Availability-enhancing gateways for network traffic in virtualized computing environments |
| WO2020152713A1 (en) * | 2019-01-25 | 2020-07-30 | Council Of Scientific & Industrial Research | Fibrinolytic composition and method of its preparation |
| CN115697385A (zh) * | 2020-05-11 | 2023-02-03 | 泰伦基国际有限公司 | 一种治疗脊髓性肌萎缩症的方法和药物 |
| CN118308334B (zh) * | 2024-06-06 | 2024-10-08 | 深圳市卫光生物制品股份有限公司 | 一种重组人纤溶酶原及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4652639A (en) | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US4774087A (en) | 1987-08-14 | 1988-09-27 | Northwestern University | Micro-size fibrinolytic plasmin |
| US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| US6312893B1 (en) | 1996-01-23 | 2001-11-06 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
| DE69739304D1 (de) | 1996-01-23 | 2009-04-23 | Operon Biotechnologies Inc | Verfahren und Zusammensetzungen zur Bestimmung von Sequenzen von Nukleinsäure-Molekülen |
| US6613508B1 (en) | 1996-01-23 | 2003-09-02 | Qiagen Genomics, Inc. | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques |
| JPH10158300A (ja) | 1996-11-28 | 1998-06-16 | Suzuki Motor Corp | 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法 |
| JP2001511362A (ja) | 1997-07-22 | 2001-08-14 | ラピジーン，インコーポレイテッド | Ｍｓにより配列決定データを相関させるコンピュータ方法およびシステム |
| AU751283B2 (en) | 1998-07-14 | 2002-08-08 | Bristol-Myers Squibb Company | Lysine binding fragments of angiostatin |
| ATE349226T1 (de) | 1998-09-29 | 2007-01-15 | Leuven Res & Dev Vzw | Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle |
| US6355243B1 (en) | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
| US6969515B2 (en) | 1999-11-13 | 2005-11-29 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| US6964764B2 (en) | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| AU2001275091A1 (en) | 2000-06-02 | 2001-12-17 | Blue Heron Biotechnology, Inc. | Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides |
| JP4047170B2 (ja) | 2000-12-21 | 2008-02-13 | トロム−イクス・ナムローゼ・フエンノートシャップ | 酵母発現ベクターおよび酵母細胞における発現による組換えタンパク質の製造方法 |
| WO2003054232A2 (en) | 2001-12-13 | 2003-07-03 | Blue Heron Biotechnology, Inc. | Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins |
| US7776026B2 (en) | 2002-02-06 | 2010-08-17 | Nuvue Technologies, Inc. | Method for vitreous liquefaction |
| DE10390418D2 (de) | 2002-02-06 | 2005-01-13 | N Zyme Biotec Gmbh | Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen |
| GB0228409D0 (en) * | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
| CN102660564B (zh) * | 2004-04-22 | 2013-05-08 | 泰勒克里斯生物治疗学公司 | 重组修饰的纤溶酶 |
| WO2007047874A2 (en) * | 2005-10-20 | 2007-04-26 | Talecris Biotherapeutics, Inc. | Recombinantly modified plasmin |
| PL2220221T3 (pl) | 2007-11-29 | 2015-07-31 | Grifols Therapeutics Inc | Rekombinacyjnie zmodyfikowana plazmina |
-
2008
- 2008-11-25 PL PL08857923T patent/PL2220221T3/pl unknown
- 2008-11-25 WO PCT/US2008/084645 patent/WO2009073471A1/en not_active Ceased
- 2008-11-25 PT PT88579230T patent/PT2220221E/pt unknown
- 2008-11-25 JP JP2010536117A patent/JP5539896B2/ja active Active
- 2008-11-25 CN CN2008801232704A patent/CN101918548B/zh active Active
- 2008-11-25 US US12/744,376 patent/US8101394B2/en active Active
- 2008-11-25 KR KR1020107014243A patent/KR101529743B1/ko not_active Expired - Fee Related
- 2008-11-25 EP EP08857923.0A patent/EP2220221B1/en active Active
- 2008-11-25 AU AU2008331545A patent/AU2008331545B2/en active Active
- 2008-11-25 NZ NZ593837A patent/NZ593837A/xx not_active IP Right Cessation
- 2008-11-25 MX MX2010005947A patent/MX2010005947A/es active IP Right Grant
- 2008-11-25 CA CA2707266A patent/CA2707266C/en active Active
- 2008-11-25 HU HUE08857923A patent/HUE024916T2/en unknown
- 2008-11-25 BR BRPI0819780-6A patent/BRPI0819780B1/pt not_active IP Right Cessation
- 2008-11-25 NZ NZ585715A patent/NZ585715A/en not_active IP Right Cessation
- 2008-11-25 ES ES08857923.0T patent/ES2534040T3/es active Active
-
2010
- 2010-05-24 IL IL205936A patent/IL205936A/en active IP Right Grant
- 2010-05-25 ZA ZA2010/03730A patent/ZA201003730B/en unknown
-
2011
- 2011-11-22 US US13/302,322 patent/US8182808B2/en active Active
-
2012
- 2012-05-03 US US13/463,437 patent/US8512980B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011505140A5 (https=) | ||
| JP2009268467A5 (https=) | ||
| CA2563675A1 (en) | Recombinantly modified plasmin | |
| EA200901430A1 (ru) | Варианты фермента аспарагиназы и их применение | |
| JP2012532601A5 (https=) | ||
| JP2018537099A5 (https=) | ||
| JP2014511698A5 (https=) | ||
| NZ606427A (en) | Extended recombinant polypeptides and compositions comprising same | |
| EP1350843A3 (en) | Alkaline cellulase variants | |
| JP2015532654A5 (https=) | ||
| NZ595498A (en) | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them | |
| JP2012525836A5 (https=) | ||
| NZ620606A (en) | Modified leptin polypeptides and their uses | |
| IL205936A (en) | Polynucleotide encoding a polypeptide having a single curling site at the homologous n-terminus to a human plasminogen ringing site, an activation site and a serine protease site at the homologous c-terminal end to parallel regions in human plasminogen, the polypeptide and cod encoding the polypeptide | |
| WO2013182910A3 (en) | Transcription activator-like effector (tale) fusion protein | |
| EP2470559A4 (en) | COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING THEM | |
| JP2007513634A5 (https=) | ||
| JP2006149395A5 (https=) | ||
| WO2005007867A3 (en) | Thermostable amylase polypeptides, nucleic acids encoding those polypeptides and uses thereof | |
| JP2009501530A5 (https=) | ||
| TW200944218A (en) | Mutants of streptokinase and their covalently modified forms | |
| JP2014525439A5 (https=) | ||
| JP2011521661A5 (https=) | ||
| RU2011154363A (ru) | Комбинации клад rrgb пневмококков | |
| JP2008536479A5 (https=) |